 AC Immune SA NASDAQ: ACIU has completed an 18-month interim assessment of safety and tolerability in the Phase 2 study evaluating ACI-24, its vaccine candidate for mild Alzheimers disease AD. No safety concerns or evidence for CNS inflammation or ARIA amyloid-related imaging abnormalities were observed, confirming earlier interim results. 